// App-Quantinova.ai

e21088 : Value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab (B) in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy (AVALUZ trial).

Researchers

Presenter

  • Manuel Codes

Principal Investigators

  • Luis Manso

  • Eva M. Ciruelos

  • Diego Perez

  • Juan L. Bayo

  • Jose Ramon Mel

  • Elena Garcia-Martinez

  • Ricardo Cubedo

  • Javier Salvador

  • Juan De la Haba- Rodriguez

  • Antonio Galan

  • Jose Manuel Baena

  • Ana Jaen

  • Miquel Gil

  • Adolfo Murias

  • Isabel Blancas

  • Encarnacion Gonzalez

Medical Centers

  • Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain

  • Pharmacy, Hospital Virgen Macarena, Sevilla, Spain

  • Hospital Costa del Sol, Malaga, Spain

  • Complejo Hospitalario Xeral Cies, Vigo, Spain

  • Hospital Ciudad de Jaen, Jaen, Spain

  • Hospital Clinico San Cecilio, Granada, Spain

  • Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Morales Meseguer, Murcia, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Pharmacy, Hospital Juan Ramon Jimenez, Huelva, Spain

  • Instituto Catalan de Oncologia, Bellvitge, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating endothelial cells

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Bevacizumab

  • Gemcitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved